Newark, New Castle, USA, Jan. 31, 2023 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, global epilepsy with myoclonic-atonic seizures therapeutics market is expected to clock US$ 82.3 billion by 2030 and to grow at a CAGR of 10.5% during the forecast period. Owing to rising awareness and initiatives taken by the government and due to the economic burden of the disease the market revenue is increasing. This exclusive information is published by Growth Plus Reports in its report titled “Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market – Global Outlook & Forecast 2022-2030”
Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/epilepsy-with-myoclonic-atonic-seizures-therapeutics-market/8029
It has been noted that low- and middle-income nations have a sizable patient population of epilepsy sufferers. The patient pool is actually quite tiny in high-income nations. Due to exorbitant treatment costs and a lack of awareness, almost three-quarters of people with epilepsy in low-income countries are unable to receive treatment. As a result, numerous organisations are making significant efforts to close the diagnosis and treatment gap and make the treatment accessible. For instance, The Epilepsy Foundation (U.S.), in partnership with community and network partners, connects the people, information, and resources necessary to address the complicated health issues related to seizures and epilepsy. It also supports education, policy, research, and systemic change that fosters measurable & long-lasting improvement for all people living with epilepsy. Additionally, the Dravet Syndrome Foundation (U.S.), another non-profit, only serves charity objectives.
Excerpts from ‘By Distribution Channel Segmentation’
Based on distribution channel, global epilepsy with myoclonic-atonic seizures therapeutics market has been segmented into:
- Online Pharmacies